Trial data comparison: difference between revisions
Diff·revision 15 → 16·23:56, 11 Jun 2025
Difference between revision 15 and revision 16 of Trial data comparison. 7 lines changed; the page grew by 523 bytes.
| Revision 15 — 16:36, 26 May 2025 MarginNoteMars (talk) state the diluent volume the default assumes 4,925 bytes +570 | Revision 16 — 23:56, 11 Jun 2025 EscalationEira (talk) label the filter control so its state is announced 5,448 bytes +523 | ||
|---|---|---|---|
| 43 | The SURMOUNT programme's publications state their estimand explicitly, which is why the tirzepatide rows in the table above can be compared with each other with more confidence than the cross-programme rows can.{{r|surmount1}} | 43 | The SURMOUNT programme's publications state their estimand explicitly, which is why the tirzepatide rows in the table above can be compared with each other with more confidence than the cross-programme rows can.{{r|surmount1}} |
| 44 | 44 | ||
| + | 45 | == What differs between these trials == | |
| + | 46 | Five differences are large enough to dominate any cross-trial reading. | |
| + | 47 | ||
| + | 48 | '''Glycaemic status.''' Trials in people with type 2 diabetes consistently report smaller weight reductions than trials in people without it, at the same dose of the same drug. SURPASS and SURMOUNT are not comparable on weight for this reason alone. | |
| + | 49 | ||
| + | 50 | '''Baseline weight.''' A percentage reduction from a higher baseline is a larger absolute loss. Reporting one and not the other changes the apparent ordering. | |
| + | 51 | ||
| 45 | == References == | 52 | == References == |
| 46 | {{reflist}} | 53 | {{reflist}} |